Last reviewed · How we verify
MK-2206
MK-2206 is an investigational AKT inhibitor studied in lung cancer and nasopharyngeal carcinoma trials, typically combined with other drugs.
MK-2206 is an AKT inhibitor evaluated in clinical trials for Non-Small Cell Lung Cancer and Recurrent Nasopharyngeal Carcinoma, often in combination with other agents. No FDA-approved indication is listed in the provided text.
At a glance
| Generic name | MK-2206 |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
The provided text does not contain a plain-English mechanism description. It only lists clinical trial summaries involving MK-2206 in combination with gefitinib, anastrozole, or fulvestrant for certain cancers.
Approved indications
Common side effects
Key clinical trials
- A Phase I Trial of Dinaciclib (SCH727965) and MK-2206 in Metastatic Pancreatic Cancer With an Expansion Cohort in Advanced Pancreatic Cancer (Phase 1)
- A Phase II Trial of Neoadjuvant MK-2206 in Combination With Either Anastrozole if Postmenopausal or Anastrozole and Goserelin if Premenopausal in Women With Clinical Stage 2 or 3 PIK3CA Mutant Estroge (Phase 2)
- A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-Expansion in Advanced HER2+ Breast Cancer (Phase 1)
- A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer (Phase 2)
- A Phase I Dose Defining Study For MK-2206 Combined With Gefitinib In NSCLC Population Enriched With EGFR Mutation (Phase 1)
- BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (Phase 2)
- Phase II Trial of MK-2206 (an AKT Inhibitor) in Combination With Endocrine Therapy in Patients With Hormone Receptor Positive Breast Cancer (Phase 2)
- A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK-2206 CI brief — competitive landscape report
- MK-2206 updates RSS · CI watch RSS
- portfolio CI